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Case presentation
A 29-year-old black woman was evaluated at another hospital be-
cause of epistaxis and a blood pressure of 300/150mm Hg. At age 18 she
was refused entrance to the military because of hypertension. Between
the ages of 20 and 24 years, she had 3 pregnancies, each complicated by
toxemia. Although hypertension was noted on occasion over the
subsequent years, she did not take any antihypertensive medications.
Her mother and 3 of her 7 siblings had hypertension.
On physical examination, the optic fundi showed grade II hyperten-
sive changes. Urinalysis revealed: specific gravity, 1.016; 1 + protein;
negative glucose; 10 red blood cells/high-power field; and no casts. The
serum creatinine was 2.0 mg/dl; endogenous creatinine clearance, 55
mI/mm; and 24-hour protein excretion, 1.2 g. Hemoglobin electropho-
resis was within normal limits. Chest x-ray and electrocardiogram
disclosed evidence of left ventricular hypertrophy. Tests for pheochro-
mocytoma were negative. An excretory urogram revealed no evidence
of refiux nephropathy; renal arteriogram showed bilateral intrarenal
small-vessel disease, which was thought to be consistent with nephro-
sclerosis.
The patient returned for only some of her scheduled followup visits
and took the prescribed antihypertensive medications only intermit-
tently. Renal function gradually deteriorated. At age 36, the serum
creatinine was 9.5 mgldl and BUN 90 mg/dl, and she was referred for
renal transplantation. At that time, she was taking hydralazine, 50 mg;
propranolol, 80 mg; and furosernide, 40 mg, all twice daily; blood
pressure ranged between 130—140/90—100 mm Hg.
After completing a donor-specific blood transfusion protocol [11, but
prior to hemodialysis, the patient received a renal allograft (one
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haplotype match) from her brother. Initial immunosuppressive therapy
consisted of cyclosporine, azathioprine, and prednisone. Although the
serum creatinine fell rapidly from 10.0 mg/dl to 1.5—2.0 mg/dl, hyper-
tension was a persistent problem in the postoperative period. Furose-
mide, propranolol, hydralazine, and clonidine produced only moderate
improvement. She developed angina pectoris, but there was no evi-
dence of acute myocardial infarction, and a coronary arteriogram
revealed normal coronary vessels. The addition of nifedipine to her
regimen gradually improved the blood pressure, with diastolic levels
averaging 90 mm Hg. The postoperative course also was complicated
by the development of diabetes mellitus, which required insulin ther-
apy. On the 32nd postoperative day, a renal scan (iodohippurate) was
normal, and effective renal plasma flow (ERPF) was 278 ml/min (within
normal limits for a renal allograft).
She was discharged on the 35th postoperative day and was advised to
take propranolol, 120 mg; hydralazine, 50 mg; and nifedipine, 20 mg, all
every 8 hours; clonidine, 0.2 mg twice daily; prednisone, 20 mg each
day; cyclosporine, 540 mg each day; and a divided-dose insulin regi-
men. Blood pressure was 150/90mm Hg and serum creatinine 1.5 mg/dl.
Because hypertension remained a problem, captopril, 25 mg three times
daily, was added. Blood pressure control improved, but the serum
creatinine rose from 1.7 to 2.6 mg/dl. Captopril was discontinued. The
blood level of cyclosporine was 800 ng/ml; the dose was reduced from
540 to 450 daily.
The patient was readmitted for further evaluation of the hyperten-
sion. Physical examination revealed a blood pressure of 160/120 mm Hg
and grade LI hypertensive retinopathy. The graft was nontender and not
enlarged; no bruit was heard. Serum creatinine ranged between 1.8 and
2.2 mg/dl, An arteriogram of the renal allograft showed a well-function-
ing kidney with no evidence of small-vessel disease within the graft. A
stenosis of the renal artery was detected; however, the estimated
luminal narrowing was only 40% (Fig. I). Captopril was administered in
a dose of 25 mg three times daily for 3 days; serum creatinine remained
stable at 2.0 mg/dl, and the pre- and postcaptopril ERPF was unchanged
(300 versus 316 mI/mm). Captopril administration again reduced the
blood pressure. Azathioprine, 75 mg/day, was started, and the cyclo-
sporine dose was reduced to 400 mg daily. Antihypertensive medica-
tions consisted of furosemide 60 mg twice daily; and propranolol, 120
mg; clonidine, 0.2 mg; nifedipine, 10 mg; and captopril, 25 mg thrice
daily.
To facilitate the response to a protocol including a normal, low, and
high salt intake (Table 1), all antihypertensive medications were dis-
continued except for clonidine; the latter was required because of the
severity of the hypertension. Blood pressure was relatively insensitive
to a low-salt diet and, after 3 days of sodium chloride restriction, plasma
renin activity was only 1.2 ng All/mI/mm. Renal vein renin concentra-
tions were low in both native kidneys (0.42 ng All/mI/mm) and in the
allograft (0.72 ng Au/mI/mm). Mean endogenous creatinine clearance
was 52 mI/mm, and urinary protein excretion was less than 100 mg/24
hours. The antihypertensive medications, including captopril, were
recommenced and the serum creatinine remained stable.
Because of refractory hypertension, both of her native kidneys were
removed; the kidneys weighed 79 and 50 g respectively, and histopatho-
logic examination revealed primary nephrosclerosis. Within one week
of the surgery, the blood pressure decreased, but the patient continued
to require hydralazine, propranolol, and furosemide. On discharge she
was given these drugs as well as cyclospormne, 320 mg; prednisone, 20
1024
Editors
JORDAN J. COHEN
JOHN T. HARRINGTON
JEROME P. KASSIRER
NIcoLAos E. MADIAS
Managing Editor
CHERYL J. ZUSMAN
University of Chicago Pritzker School of Medicine
and
Tufts University School of Medicine
Hypertension in renal transplant recipients 1025
Fig. 1. Angiogram of renal allograft. Stenosis was assessed as causing
40% reduction of diameter of vessel.
Table 1. Protocol for study of hypertensive and normotensive renal
transplant recipients
Diet
• 3 days on 150 mEq Na diet
• 3dayson9mEqNadiet
• 3 days on intravenous infusion of 0.15 M NaC1 at 3.8 mEq/kg
body wt/day
Procedure
• Supine and 30° tilt measurement of plasma renin activity, plasma
aldosterone, and plasma norepinephrine after each 3-day period
• Daily measurement of mean arterial pressure, urinary sodium
and creatinine, and body weight
• Measurement of cardiac output and plasma volume after each
3-day period, ERPF at end of study
mg; and azathioprine, 200 mg daily. On followup by a local nephrolo-
gist, blood pressure consistently has been within the normal range, and
the antihypertensive therapy is being reduced.
Discussion
DR. ROBERT G. LUKE (Director, Division of Nephrology and
Nephrology Research and Training Center, and Professor of
Medicine, University of Alabama at Birmingham, Birmingham,
Alabama): Before discussing the specifics of the severe post-
transplant hypertension in this patient, I would like to review
the topic in a more general manner. I will consider several
aspects of hypertension in this setting, including the incidence,
importance, causes, pathophysiology, diagnostic approach, and
the surgical and medical treatment. In this discussion I will
draw on my experience in renal transplantation since 1969 at the
University of Kentucky Medical Center and since 1979 at the
University of Alabama Medical Center, and on an extensive
series of studies performed in the General Clinical Research
Center (GCRC) at our medical center under the joint direction
of Dr. John J. Curtis and me. In the course of these studies we
have made some observations that we believe are relevant to
hypertension in a more general sense. These include (1) the role
of the kidneys in the pathogenesis of so-called "essential
hypertension," (2) the diagnosis of renovascular hypertension,
and (3) the mechanism of cyclosporine-associated hyperten-
sion.
Incidence. The incidence of hypertension is approximately
80% in the immediate posttransplant period [2—4]; after renal
transplantation most patients require at least diuretic therapy
prior to discharge. In the majority of patients, hypertension
gradually improves as the steroid dose is reduced; in many,
antihypertensive drugs can be discontinued altogether, espe-
cially if renal function remains good. Most surveys of stable
transplant patients receiving maintenance immunosuppressive
treatment, however, continue to show a relatively high preva-
lence of hypertension, approximately 50% [3—8]. Most patients
have mild to moderate hypertension, but in some series 10% to
20% of those who are hypertensive have severe or accelerated
hypertension [3, 6].
In a survey of all patients receiving renal transplants over a
decade at the University of Kentucky Medical Center and who
were alive and had a functioning kidney for at least 6 months,
we observed an overall prevalence of hypertension of 24% [9].
All such patients in our clinic at that time were receiving
steroids on alternate days; the average maintenance dose was
22 mg every other day. We debated whether or not our lower
prevalence resulted from the use of alternate-day prednisone; I
will return to this topic later. The most important finding,
however, was that the prevalence of hypertension was only 6%
in the 32 patients who shared three characteristics: (1) they had
received a kidney from a living-related donor; (2) they all had
had a bilateral nephrectomy; and (3) they all had a stable serum
creatinine of less than 2.0 mgldl (Fig. 2). This percentage of
hypertension is even lower than that in the general population
and demonstrates that patients with a well-tolerated allograft
who receive maintenance immunosuppressive therapy need not
be hypertensive, especially if the native kidneys have been
removed. The significance of retained native kidneys will be
considered subsequently, as will the possible contribution of
cyclosporine to the prevalence of hypertension. In this study
we also observed, as have others, that the prevalence of
hypertension was high in the presence of chronic rejection [7,
10, 11]. Overall, chronic rejection is the most frequent cause of
hypertension in renal transplant recipients after the first few
months [7, 10, 11].
Factors not associated with an increased prevalence of hy-
pertension are age, sex, nature of the original renal disease, and
maintenance dose of steroid [4, 9, 12]. Some data suggest that
the presence of persistent hypertension in patients undergoing
dialytic therapy is predictive of sustained posttransplant hyper-
tension [6, 13]. Because persistent hypertension despite either
adequate ultrafiltration on dialysis or after successful transplan-
tation is likely renin-dependent, one might anticipate such an
association in patients with retained native kidneys. Neverthe-
less, most patients with a well-tolerated graft eventually be-
come normotensive despite the presence of the native kidneys.
This could be due to a diminution in renin secretion by
progressive scarring of the native kidneys. However, increased
renin release from the native kidneys in response to a stimulus
such as furosemide administration (and remission of hyperten-
sion after bilateral nephrectomy) occurs as late as 6 years after
successful renal transplantation [11, 14—16]. In summary, the
following factors are associated with an increased incidence of
hypertension in patients followed for a long time after renal
transplantation: impaired renal function; cadaveric donor;
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Fig. 2. Association of renal function, bilateral nephrectomy (Bilat Nx)
and living-related donor (LRD) or cadaveric (CAD) graft with preva-
lence of hypertension in renal allograft recipients. The numerator at the
bottom of each column indicates the number of hypertensive patients;
the denominator indicates the total number of patients reviewed that
have the indicated factor(s) present. From Ref. 9.
Years after GCRC admission
Fig. 3. Allograft survival of 52 renal transplant recipients who partici-
pated in our General Clinical Research Center protocol studies. All
patients were at least 1 year beyond their transplant operation and had
a serum creatinine of <2.0 mg/dl. All were considered at risk for
allograft failure after completion of this hospital admission, and none
had been lost to followup. Recipients of either cadaver (7 patients) or
related-donor (10 patients) allografts are combined in the normotensive
controls (solid line). Note that such normotensive recipients whose
serum creatinine is <2.0 mg/dl at 1 year have excellent long-term
allograft survival regardless of the source of the kidney. Also, the
selected hypertensive patients with allografts from cadavers (dotted
line) and the hypertensive patients with living-related donor allografts(dashed line) usually have severe or at least moderate hypertension.
Because all patients were 1 year beyond transplantation at study,
allograft survival 3 years after sudy is equivalent to 4-year survival after
transplantation. From Ref. 22.
1. Immunosuppressive therapy
Steroids
Cyclosporine
2. Allograft failure
Chronic rejection
Recurrent disease
3. Potentially surgically remediable causes
Allograft renal artery stenosis
Native kidneys
4. Speculative cause
Recurrent essential hypertension
As primary cause of ESRD
From (pre-) hypertensive donor
quent cause of allograft loss and of hypertension [24]; however,
recurrent idiopathic focal glomeruloscierosis frequently is as-
sociated with hypertension, especially if the patient previously
had "malignant" focal glomerulosclerosis [24]. Causes of
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retained native kidneys; and, as I will discuss in a moment,
chronic cyclosporine administration.
Importance. Cardiovascular events remain the most impor-
tant cause of death in patients with end-stage renal disease who
have been treated by renal replacement therapy [17]. Hyper-
tension probably is the most important risk factor for cardio-
vascular morbidity and mortality in dialyzed as well as trans-
plant-treated patients [4, 18]. Cardiovascular problems are the
major cause of mortality following renal transplantation, espe-
cially after the first few months [8, 19, 20]. The impact of
hypertension is also demonstrated by a Health Care and Fi-
nance Administration survey, which showed (prior to the use of
cyclosporine) that the cost of antihypertensive therapy often
exceeded that of maintenance immunosuppression after the first
year [21]. In addition, hypertension clearly is negatively corre-
lated with graft survival (Fig. 3) [4, 22]. Hypertension, of
course, possibly represents merely an indicator of underlying
chronic rejection, and the latter may be the primary cause of the
increased graft loss [23]. However, as in primary renal paren-
chymal disease, hypertension probably accelerates the rate of
loss of nephrons. In contrast, if the transplant was performed at
least one year earlier and the patient has a normal serum
creatinine and blood pressure, and if the patient is receiving
maintenance doses of immunosuppressive drugs, the outlook
for long-term graft survival appears to be excellent.
Causes. Causes of hypertension in renal transplant recipients
are given in Table 2. Overall, the most common cause of
hypertension in a renal transplant clinic is probably chronic
rejection. Recurrent renal disease now appears to be an infre-
Table 2. Causes of posttransplant hypertension
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Fig. 4. Mean arterial pressure in hypertensive transplant patients and in
patients with essential hypertension. Each bar represents the average
mean arterial pressure of the entire group of patients (hypertensive
transplant recipients and nontransplant patients with essential hyper-
tension). Note that the patients with essential hypertension have
significant changes in group average pressure that correspond to
changes in sodium intake. The transplant patients do not have similar
changes. From Ref. 22.
allograft renal artery stenosis are: (1) "rejection" of the donor
artery; (2) atherosclerosis of the recipient vessel; (3) clamp
injury of the recipient vessel; and (4) kinking or fibrosis at the
anastomosis. The most common is that associated with abnor-
malities of the donor artery; these may be caused, at least in
part, by rejection.
Routine maintenance prednisone therapy (10—15 mg/day)
probably does not contribute in a major way to hypertension.
The higher doses used in the immediate posttransplant period,
especially when acute rejection is being treated, might contrib-
ute to the high prevalence of early hypertension. The mecha-
nisms by which glucocorticoids induce hypertension are not yet
established, but these likely include a mineralocorticoid effect
at high levels and a sensitization of arterioles to other circulat-
ing vasoconstrictor agents [25]. There is evidence that dose
spacing of glucocorticoid as well as the total dose ingested
might contribute to hypertension [22]. In a retrospective study
of matched patients, we found a significant drop in blood
pressure in a group given the same total dose of steroid on
alternate days as compared with a group continuing with daily
steroid ingestion [221. In a 6-week crossover study of patients
changed from alternate-day to daily maintenance steroid ther-
apy, we did not observe a significant increase in blood pressure.
There was, however, a significant increase in body weight
during daily prednisone administration [261; increased weight
gain has been associated with increased posttransplant hyper-
tension [4, 7, 12]. Conclusions from prospective studies of the
effects of alternate-day steroid administration on blood pressure
differ [27, 28].
Pathophysiology. It is likely that the pathogenesis of the
hypertension commonly associated with chronic rejection ap-
proximates that of hypertension secondary to chronic renal
parenchymal disease; the prevalence of hypertension in the
latter setting is 80% to 90% in most series [3, 29]. The histology
of chronic rejection most closely resembles that of nephroscle-
rosis, with prominent narrowing in small vessels, although a
chronic transplant glomerulopathy also occurs. Salt wasting as
a complication of chronic rejection is rare and this might partly
explain the frequency of associated hypertension.
I now would like to discuss the pathophysiology and the other
causes of posttransplant hypertension by describing an ongoing
series of studies that Dr. John J. Curtis and I are carrying out in
the General Clinical Research Center at our institution. To
minimize chronic rejection as a cause, all patients studied had a
stable serum creatinine of less than 2.0 mgldl, a 24-hour protein
excretion less than 200 mg, were at least one year posttrans-
plant, and were taking maintenance prednisone without any
recent episodes of acute rejection. The protocol is outlined in
Table 1. Hypertension was defined as a mean arterial pressure
of greater than 105 mm Hg (measured 5 times daily for 3 days
during ingestion of a normal sodium chloride intake under
standardized hospital conditions). We have studied more than
100 patients, including 40 patients who were normotensive.
A comparison of 22 hypertensive renal transplant recipients
with 21 unmatched patients, who had intact renal function and
essential hypertension and were studied separately according to
the same protocol by Dr. Harriet Dustan in our GCRC, revealed
a striking difference in the salt-sensitivity of the two groups
(Fig. 4). Others have supported the lack of importance of a
high-salt diet in the genesis of posttransplant hypertension [30,
31].
In a subsequent comparison between 33 hypertensive renal
allograft recipients and 23 normotensive recipients, the most
striking differences were enhanced activity of the renin-angio-
tensin system, decreased ERPF, and higher renal allograft
vascular resistance in hypertensive patients [321. Reduced
ERPF with maintained GFR has been shown previously [33,
34]. Demographic characteristics and maintenance immunosup-
pressive therapy were similar in the two groups. It is interesting
that plasma renin activity was significantly higher for the
hypertensive patients in a tilted or supine position both on the
normal- and high-sodium intake but not on the low-sodium
intake. Thus stimulation of the renin-angiotensin axis was not
associated with increased differences between normotensive
and hypertensive transplant patients. Changes in mean body
weight, plasma volume, and urinary sodium excretion did not
differ between the two groups, but mean arterial pressure again
remained constant in the hypertensive transplant group during
the three different salt intakes. This finding contrasted with the
significant fall in blood pressure in the normotensive transplant
patients eating a low-salt intake and a subsequent significant
increase in blood pressure with a high-salt intake. Followup
investigation of the 33 hypertensive patients revealed 5 (15%)
with chronic rejection and 6 (18%) with renal artery stenosis; of
the remaining 22 patients, 21(64%) had retained native kidneys.
Allograft vascular resistance also was significantly increased as
compared with normotensive transplant patients in the individ-
ual subgroups of patients with retained native kidneys, with
renal artery stenosis, and with initially occult chronic rejection
(defined as those in whom subsequent followup, including renal
biopsy in 3 patients, revealed that diagnosis) (Table 3). Al-
though all patients met the outlined admission criteria, there
was an initial significantly lower endogenous creatinine clear-
Essential
hypertensive patients
(N= 211
1 234567891011 1 234567891011
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Table 3. Comparison of hypertensive subgroups with normotensive
renal transplant recipients
Effective
Endogenous renal Renal
creatinine plasma vascular
clearance flow resistance
Group N (mi/mm) (mi/mm) (mm Hg/mi/mm)
Normotensive 23 83 l4 356 124 28 7
Retained NKb 21 77 19 268 114C 53 25C
RASd 6 66 18 240 89C 57 24C
Occult CR 5 53 IOC 224 59C 53 15C
a Mean SD.
b NK denotes native kidneys.
P < 0.05 versus normotensive control.
d RAS denotes renal artery stenosis.
CR denotes chronic rejection.
ance only in the occult chronic rejection group. Our subsequent
studies suggest that the major factor increasing intrarenal
vascular resistance (in the allograft) in patients with retained
native kidneys is renin secretion by the native kidneys. For the
hypertensive transplant group as a whole, further support for
the overall importance of renin in the pathogenesis of hyper-
tension is provided by the response to a test dose of 12.5 mg of
captopril: the hypotensive response (LBP —11 1.3 versus
—5 1.7 mm Hg, mean SEM, P < 0.02) was greater in the
hypertensive than in the normotensive recipients [231.
When we compared 6 one-kidney hypertensive patients with
27 three-kidney patients (that is, those with retained native
kidneys), renin response did not differ between the two groups,
although it has been suggested that single-kidney hypertensive
patients are not likely to be "renin-dependent" [311. Further-
more, chronic rejection or renal artery stenosis was found in 5
of the 6 one-kidney patients and in only 6 of the 27 three-kidney
patients.
Diagnostic and therapeutic approach. As in the evaluation of
patients with non-transplant-related hypertension, consider-
ation first must be given to hypertension that is potentially
remediable by surgery or angioplasty in the renal transplant
recipient. Therapy in the latter case would include native-
kidney nephrectomy [6, 10, 11, 351 or surgical arterial repair or
percutaneous angioplasty of allograft renal artery stenosis. A
recent Nephrology Forum discussed in detail the difficulty of
diagnosing functionally significant renal artery stenosis (as
demonstrated by cure or significant improvement in blood
pressure after an adequate duration of followup following
correction of the lesion by surgery or angioplasty) [361. Physical
examination, including the finding of an allograft bruit, is of
little diagnostic value [37]. The problem is compounded in the
patient with a renal allograft because of the absence of a
contralateral kidney for comparison of rates of excretion of
radioisotopic and contrast agents and of renal vein renin levels.
Furthermore, unlike native kidneys with functionally significant
renal artery stenosis, collateral circulation does not develop.
Until recently, one could assess functional significance only by
the radiologic assessment of the degree of arterial narrowing
and the knowledge that distal blood flow is likely to be reduced
only when the diameter of the vessel is narrowed by approxi-
mately 60% to 70% [38].
Thus a practical test of the functional significance of renal
GFR
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Fig. 5. Status of a single glomerulus distal to a significant renal artery
stenosis. Prior to administration of a converting enzyme inhibitor, the
afferent arteriole is dilated and the angiotensin-constricted efferent
arteriole maintains GFR. After administration of a converting enzyme
inhibitor and a diuretic, systemic blood pressure (BP) and extracellular
fluid (ECF) volume fall. Renal perfusion pressure distal to the stenosis
may also fall, and because of efferent vasodilation, an acute reduction
in GFR occurs. RAS = renal artery stenosis; AFF = afferent renal
arteriole; EFF = efferent renal arteriole.
artery stenosis in allografts is needed. The effect of the acute
administration of captopril on glomerular filtration rate might be
such a test, although the value of this approach is not yet
formally and prospectively established [39]. Our own early
experience comprises 18 patients in whom eaptopril adminis-
tration was associated with an abrupt, but rapidly reversible,
fall in GFR; these patients all have had a decrease in blood
pressure in response to angioplasty or surgery that persisted for
at least the first few months after the procedure. Our working
hypothesis is that pressure and flow are reduced beyond the
normal autoregulatory range distal to a functionally significant
stenosis; GFR in those circumstances would fall unless main-
tained by selective constriction of the efferent arteriole by
angiotensin II [40, 41] (Fig. 5). A positive response of GFR to
converting enzyme inhibition would be present in any situation
in which all functioning nephrons are distal to a functional
stenosis, as in a single native kidney or in bilateral renal artery
stenosis. A positive response also might be seen in severe
volume depletion or congestive cardiac failure when GFR again
depends on angiotensin 11-induced constriction of the efferent
arteriole and during administration of converting enzyme inhib-
itors to patients with severe intrarenal small-vessel disease, as
in severe chronic rejection or scleroderma [42]. In testing for
functional allograft stenosis in this manner, we and others have
routinely employed a diuretic, which may help to increase the
"renin-dependence" of the maintenance of GFR in the pres-
ence of mild volume contraction [41, 43, 44]. Other possible
mechanisms contributing to the fall of GFR that occurs subse-
quent to captopril administration (for example, increased
bradykinin production, changes in prostaglandin synthesis) are
not excluded [45—47]. We also have noted a tendency for the
ERPF in the affected graft to fall subsequent to captopril
administration; this decrease may be due, at least in part, to an
artifact secondary to a drop in the renal extraction ratio of
iodophippurate in these circumstances [48].
It is not established that patients who maintain stable renal
function following administration of converting enzyme inhibi-
tors do not have functionally significant stenosis. Angioplasty in
2 such patients did not lower their blood pressure, however
(personal unpublished data). Clinical comparisons in the same
patients suggest that converting enzyme inhibitors' ability to
reduce GFR is not simply due to the production of a lower
systemic blood pressure than that obtained with other antihy-
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pertensive agents [39, 49]. We currently are engaged in a
prospective study to compare the effects of converting enzyme
inhibition on GFR with those induced by other antihypertensive
agents at the same level of blood pressure. Desmond, Cheung,
and Fang reported reversible renal failure following the use of
nifedipine in patients with chronic renal insufficiency and
severe renal vascular disease; it is possible that a reduction in
cytosolic calcium could interfere with the GFR-maintaining
effects of angiotensin II within the kidney [50]. The acute renal
failure occurring in response to converting enzyme inhibition is
usually rapidly reversible; if the drug is continued, the serum
creatinine level may reach a new, steady-state elevated level or
the patient can develop oliguric renal failure. The serum creat-
mine should be checked within several hours of, and certainly
within 24 hours of, initial administration of a converting enzyme
inhibitor. In our experience this increase in serum creatinine
occurs within the first 48—and most commonly the first 24—
hours after captopril treatment is begun.
Converting enzyme inhibition also has been used successfully
to increase the diagnostic accuracy of isotope renography with
differential renal plasma flow and GFR measurements in pa-
tients with renovascular hypertension due to renal artery
stenosis affecting one of the two native kidneys [481. In a large
prospective study of patients with renovascular hypertension,
Franklin and Smith showed a significant association between
high-grade (>80%) renal artery stenosis and renal insufficiency
after the administration of enalapril (a converting enzyme
inhibitor) and hydrochlorothiazide [491.
The detected prevalence of renal artery stenosis in allografts
depends on the indications for performing renal angiography. In
circumstances in which angiography has been performed rou-
tinely, anatomic stenosis has been observed in up to 23% of the
patients [51]. Functionally significant stenosis, in contrast,
occurs in approximately 5% of renal transplant recipients [52,
53]. However, in selected clinical circumstances, such as in our
one-kidney patients with unanticipated hypertension, whom I
already mentioned, the prevalence of functionally significant
stenosis can approach 20% [4]. The increasing availability of
angioplasty is especially valuable for renal artery stenosis in an
allograft because previous surgery causes periarterial fibrosis
and scarring; operative repair is more difficult than for renovas-
cular lesions in a native kidney and there is more risk of loss of
all renal function [54, 55]. There is not yet evidence in the
literature of long-term followup of angioplasty-treated renal
artery stenosis in allografts, although in the relatively short
term the technique has shown success rates similar to those for
treating renal artery stenosis in native kidneys [55, 56].
Native-kidney nephrectomy or embolization [57] are safer
procedures than are angioplasty or vascular repair of allograft
stenosis, certainly as far as graft function is concerned [40]. We
reported a small group of carefully selected patients in whom
bilateral nephrectomy dramatically decreased blood pressure
and markedly increased renal allograft plasma flow [58] (Fig. 6).
In a subgroup of these patients, captopril administration prior to
surgery produced a similar increase in renal plasma flow to that
produced later by bilateral nephrectomy, whereas administra-
tion of the same dose of captopril to the same patients after
removal of the native kidneys did not alter ERPF (Fig. 7). These
data suggest that the major mechanism of renal vasoconstric-
tion is renin secretion from the native kidneys. Other mecha-
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Fig. 6. Changes in renal function, body weight, and plasma volume
after nephrectomy. ERPF (effective renal plasma flow), RVR (renal
vascular resistance), and FF (filtration fraction) are compared in 6
patients before and after native-kidney nephrectomy. PV = plasma
volume. There is a significant increase in ERPF, and significant
decreases in RVR and FF. BP (not shown) also fell significantly to
normal levels. From Ref. 58.
nisms such as abnormal afferent nerve signals with an efferent
effect on the allograft [59] via circulating catecholamines or via
sympathetic reinnervation of the allograft also might be at play.
There is evidence of a larger increase in renal vascular resist-
ance in native-kidney-related hypertension than in systemic
vascular resistance, as shown by a 55% decrease in renal,
versus a 12% decrease in systemic, vascular resistance [58]. We
selected a group of patients with severe hypertension in whom
clinical circumstances that I discussed earlier suggested native-
kidney-dependent hypertension; our findings with captopril are
not necessarily applicable to patients with milder forms of
hypertension. Furthermore, the routine use of cyclosporine in
many centers at present and the phenomenon of cyclosporine-
induced renal vasoconstriction—a vasoconstriction that does
not appear to be sensitive to converting enzyme inhibitors—
may further complicate the interpretation of the patient's
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Fig. 7. Changes in MAP (mean arterial pressure) and ERPF (effective
renal plasma flow) after captopril administration both before removal of
native kidneys (dotted bars) and compared with 1 week after nephrec-
tomy (striped bars) in 7 patients. The mean changes are not significantly
different. From Ref. 58.
response to converting enzyme inhibitors, as in the woman we
are discussing today.
In patients who have well-tolerated allografts, no recent
rejection, are at least one year posttransplant, and have mild
hypertension, it seems reasonable to consider cautiously con-
verting therapy to an every-other-day prednisone regimen.
Treatment should be changed over several months to minimize
the chance of late acute rejection. As I stated earlier, I don't
believe that maintenance prednisone contributes importantly to
the pathogenesis of moderate or severe hypertension in the
renal allograft recipient [4, 61.
In considering surgical therapy for posttransplant hyperten-
sion, the following questions are important: (1) Is the allograft
free of disease? A renal biopsy may be required in some
patients to establish an answer. (2) Is transplant renal artery
stenosis, if present, functionally significant? (3) Will removal of
the native kidneys result in improvement or cure of hyperten-
sion? (4) Is it safer to continue antihypertensive medical ther-
apy and/or to consider alternate-day prednisone? In younger
patients with well-tolerated allografts who appear likely to have
many years of sustained renal function and who require multi-
ple antihypertensive agents for control of blood pressure,
nephrologists should consider the possibility of native-kidney
nephrectomy. In our selected hypertensive patients, retained
native kidneys could have contributed to hypertension in two-
thirds of cases [15, 581. Apart from the possible effects of
systemic hypertension on the allograft, prolonged vasoconstric-
tion ultimately could impair allograft function and result in
nephron loss, but this pathogenetic mechanism has yet to be
proved. Arteriolar nephrosclerosis has been seen even in
normotensive patients with Bartter's syndrome or familial
chloride diarrhea who have sustained elevation of angiotensin II
levels over many years [60, 611. My argument for posttransplant
native-kidney nephrectomy in selected hypertensive patients
should not be misinterpreted as an argument for pretransplant
nephrectomy. It would be a mistake if we again made pretrans-
plantation native-kidney nephrectomy routine, because this
procedure is associated with significant morbidity and mortality
in patients on dialysis [62], and because most patients with
successful renal transplantation become normotensive despite
retained native kidneys. Furthermore, such a policy would
result in the return of many more patients to dialysis in an
anephric state with the associated lower hematocnt and other
possible harmful effects.
The vasoconstrictive effect of the native kidneys on the
allograft kidney is comparable to the effects of the stenotic
kidney on the contralateral kidney as described by Ploth in
unilateral renal artery stenosis [63]. This finding is in keeping
with Guyton's hypothesis that the presence of a normally
functioning kidney excludes chronic hypertension [64]. Thus,
the effects of the stenotic kidney on the ipsilateral kidney in the
patient who has not received a transplant, or of the retained
native kidneys on the allograft, prevent the ipsilateral kidney or
the allograft from excreting sodium chloride in the normal
fashion, and thus from restoring normotension.
In summary, our approach to sustained significant hyperten-
sion after the first 6 to 12 months of posttransplant followup is
that one initially consider intrinsic disease of the allograft, such
as chronic rejection, recurrent primary disease, or obstruction
of the urinary tract. One practical clinical point is that espe-
cially careful consideration must be given to the diagnosis of
allograft renal artery stenosis or occult chronic rejection in a
single-kidney patient with persistent hypertension despite well-
maintained renal function. Others have pointed out the renal
hemodynamic similarities between chronic rejection and func-
tionally significant renal artery stenosis [34].
Consideration for bilateral nephrectomy or for functional
renal artery stenosis should be given if renal function is well
preserved, there have been no recent rejection episodes, the
patient is receiving a low maintenance dose of steroids, is a
reasonable surgical candidate, and requires multiple antihyper-
tensive drugs. The patient should be given a test dose of a
converting enzyme inhibitor and a diuretic, and serum creati-
nine and blood pressure should be measured carefully over the
next 12 to 48 hours. If the serum creatinine concentration rises
significantly without an excessive fall in blood pressure, then
renal angiography should be considered (after the serum creat-
mine returns to its baseline value). If the serum creatinine does
not change, the ERPF should be measured with the patient still
receiving captopril; if the ERPF increases (as compared to its
pre-captopril value) bilateral nephrectomy should be consid-
ered. The mean increase in ERPF in our small published series
was 77% [58]: we do not know how much of an increase
indicates conclusively that renin or other humoral agents from
the native kidneys are affecting the allograft. This issue is
further confounded by the vasoconstrictive effects of cyclo-
sporine, as in the patient today. Renal vein renin levels, in our
hands at least, have not been helpful in predicting the response
of the blood pressure to bilateral nephrectomy, or to repair or
angioplasty of renal artery stenosis [15]. Allograft renin secre-
tion can be elevated because of major renal vessel disease,
intrarenal small vessel narrowing, or parenchymal renal dis-
ease. Blood flow in the native kidneys is obviously very low,
and accurate renal vein secretion rates are difficult to measure.
Opinions on the utility of measuring allograft and native-kidney
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Fig. 8. Decrease in RVR (renal vascular resistance) in 14 patients
switched from cyclosponne to azathioprine.
renal vein renin levels are divided, although most studies
suggest it is of dubious value [4,6, 11, 16, 17, 65].
Cyclosporine-associated hypertension. The evidence that
currently used doses of cyclosporine in recipients of heart, bone
marrow, and liver transplants are associated with an increased
incidence of hypertension is convincing [66—70]. Similarly,
cyclosporine-related hypertension occurs in non-transplant pa-
tients treated for various immunologic diseases [71]. Support of
an increased incidence of this type of hypertension in renal
allograft recipients exists [72—751, but proof is more difficult to
obtain because of the numerous other causes of hypertension. If
cyclosporine is associated with fewer episodes of acute rejec-
tion and better graft survival, and this certainly seems to be so,
one might anticipate a lower incidence of chronic rejection and
thus a lower incidence of hypertension. However, because the
mean serum creatinine undoubtedly is higher in stable patients
managed by cyclosporine, this reduced GFR might lead to an
increased incidence of hypertension. Finally, if cyclosporine is
associated directly or indirectly with renal retention of sodium
chloride, the consequent alterations in volume also would tend
to increase the likelihood of hypertension. We have evidence
that cyclosporine produces chronic renal vasoconstriction in
humans and that, at least in the first year after renal transplan-
tation, the vasoconstriction is reversible when the drug is
discontinued [76]. This finding in humans is not surprising given
the abundant evidence in animal studies that cyclosporine acts
as a renal vasoconstrictor. In these animal studies, renal
vasoconstriction is only slightly influenced by converting en-
zyme inhibitors. Reports conflict regarding the effect of
cyclosporine on the renin-angiotensin system in humans and in
animal models of cyclosporine toxicity [77—79]. We studied 14
patients in whom cyclosporine was replaced by azathioprine for
financial reasons only. The patients were studied over one
month, 6 to 12 months after transplantation; serum creatinine
was stable and less than 2.0 mgldl in all. In comparison to the
previous period on azathioprine, ERPF increased significantly
by 36% [761 despite a slight but significant decrease (7%) in
mean arterial pressure and no significant change in serum
creatinine (1.71 0.06 to 1.67 0.10, P NS). Calculated
renal vascular resistance was higher in cyclosporine-treated
patients (Fig. 8). The mean daily cyclosporine dose in the 14
patients in whom renal vasoconstriction was present was 600
44 mg; the whole blood level was 519 55 ng/ml. In additional
balance studies performed according to the identical protocol as
for the azathioprine patients, we saw no evidence for suppres-
sion or stimulation of the renin-angiotensin-aldosterone system
in 16 patients receiving cyclosporine as compared with a
matched group of 16 patients receiving azathioprine. In our
recent preliminary studies, captopril administration produced
no increase in ERPF in 5 hypertensive three-kidney patients
receiving cyclosporine.
The evidence thus supports an increased incidence of hyper-
tension among cyclosporine-treated patients, at least in part
because of a renin-independent renal vasoconstricting effect,
which is likely to impair renal regulatory control of blood
pressure; any associated increase in systemic peripheral resist-
ance also would contribute to hypertension. Evidence exists for
a cyclosporine-induced inhibition of a prostacycline-stimulating
factor (a lymphokine?), which would allow thromboxane-in-
duced vasoconstrictor predominance [80, 81]. Animal studies
have shown that cyclosporine stimulates the sympathetic ner-
vous system, including the renal afferent and efferent nerves
[82]. In that regard, our recent finding of renal vascular con-
striction 2 weeks after renal transplantation, before renal
reinnervation has occurred [83], suggests that direct neural
vasoconstriction cannot be the only mechanism producing
hypertension. In our balance studies on patients taking cyclo-
sporine, plasma catecholamine levels were not elevated over
the levels observed in the patients treated with azathioprine. If
the mechanism of cyclosporine-induced hypertension relates to
renal vasoconstriction, one might either treat this vasoconstric-
tion pharmacologically or determine whether, at lower dosage
levels, the immunosuppressive effect can be maintained without
the vasoconstrictive effect. Triple-drug regimens combining
lower dosages of azathioprine, cyclosporine, and prednisone
are being investigated presently in various programs.
Speculative causes of hypertension. Because essential hyper-
tension is commonly regarded as a systemic disease that
secondarily involves the kidney, one might argue that this
hypertension should persist after successful transplantation.
Unlike diabetes mellitus, which clearly can lead to recurrent
diabetic renal disease in an immunologically well-tolerated
allograft [84], this sequence of events does not occur in essen-
tial hypertension. Admittedly, persistent or recurrent essential
hypertension would be difficult to prove because of the many
acquired causes of hypertension in the transplant patient,
including occult chronic rejection and immunosuppressive ther-
apy with prednisone and/or cyclosporine.
Guyton has argued that sustained hypertension does not
develop in the presence of normal renal function unless some
factor such as nonphysiologic secretion of a hemodynamically
active hormone interferes with normal renal regulation of
extracellular fluid and vascular volume [64]. There now is an
extensive series of experiments documenting in syngeneic rat
strains the successful "transplantation," that is, transfer, of
hypertension with a "hypertensive" kidney and the successful
cure of hypertension with transplantation of a "normotensive"
kidney [85, 86]; in all cases recipient rats are subjected to
bilateral native nephrectomy. Marginal evidence in humans
supports the possibility of transmission of hypertension with a
kidney from a donor who has a hypertensive parent or parents,
but again, this is extremely difficult to prove because of the
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numerous other causes of posttransplant hypertension [87]. We
have been able to show sustained remission, if not cure, of
severe essential hypertension in a small group of patients [881;
our longest followup with sustained normotension is 10 years
after transplantation. Indeed, this sequence of events might yet
occur in the patient presented today. Strong evidence suggests
that an abnormality of the kidney or some unique interaction
between an environmental effect and/or another organ or hor-
monal system and the kidney produces essential hypertension,
thus supporting Guyton's hypothesis as well as the implications
of the rat transplantation studies for humans. When we applied
our findings in the selected group of patients [88] to our
transplant clinic patients in general, we found that 22% of these
patients (81 patients) had been diagnosed as having primary
nephrosclerosis as a cause of their end-stage renal disease. Of
the 81 patients, 33 had, at the time of assessment, at least one
year of followup, a previous bilateral nephrectomy, and a stable
serum creatinine of less than 2.0 mg/dl. Of the 33 patients, 25
(76%) were normotensive and were taking no antihypertensive
medications. This percentage is similar to that in our patients
who have primary renal diseases such as chronic glomerulone-
phritis, and supports our hypothesis that successful renal trans-
plantation can produce a remission in essential hypertension.
Many mechanisms of sustained hypertension seem to depend
on selective renal vasoconstriction. Evidence supports this
pathophysiology in early essential hypertension [89]. An abnor-
mal renal vascular response in essential hypertension could lead
to inadequate excretion of sodium chloride. The fact that
native-kidney nephrectomy and that discontinuing cyclosporine
improve both aliograft blood flow and hypertension, and that
correction of renal artery stenosis increases renal plasma flow
in the contralateral kidney [63] provide tantalizing hints that
searching within the kidney for the cause of essential hyperten-
sion might be rewarding.
To return to our patient today, the diagnosis of primary
hypertensive nephrosclerosis as a cause of her chronic renal
failure found support in her race, family history, episodes of
accelerated hypertension, the exclusion of other causes, 24-
hour urine protein excretion of approximately 1 g, findings on
renal arteriography, and histology of the removed kidneys.
Possible causes of posttransplant hypertension in this patient
that we considered at various stages in her course were renal
artery stenosis, chronic rejection, native-kidney-related hyper-
tension, cyclosporine-induced hypertension, and recurrence of
essential hypertension. Her blood pressure remained trouble-
some 3 months after transplantation, and an arteriogram re-
vealed no evidence of small-vessel disease in the allograft. The
renal artery stenosis was believed to be not functionally signif-
icant both because of its appearance and, more importantly,
because there was no change in the serum creatinine level
during administration of captopril.
The patient also illustrates the problems of clinical investiga-
tion in this severe type of hypertension. We were unable to
discontinue the clonidine, which inhibits renin, during our
studies. Also, renal vein renin measurements, which are a part
of our protocol, were low both from the native kidneys and
from the allograft. However, we have not found these measure-
ments helpful even in the absence of drugs that interfere with
renin release. Because of the severity of the hypertension and
her requirement for multiple antihypertensive drugs, bilateral
nephrectomy was performed approximately 6 months after
transplantation. We believe that the failure of ERPF to increase
during captopril administration prior to bilateral nephrectomy
was due to cyclosporine's vasoconstrictive effect. At similar or
higher dose levels of cyclosporine in cardiac transplant recipi-
ents, Dr. Bryan Myers has seen no evidence of a change in renal
extraction ratios of PAH at one month after surgery (personal
communication). This is important because cyclosporine would
give a false-positive reduction in ERPF if the extraction ratio of
iodohippurate fell in such patients even with well-maintained
renal function. At her most recent examination a few weeks
ago, we reduced her cyclosporine with an eventual goal of
decreasing the dosage to 200 mg/day (2.5 mg/kg); serum creat-
mine was 1.7 mg/dl and blood pressure 120/90 mm Hg. In
addition to cyclosporine, 250 mg/day, she was receiving azathi-
oprine, 100 mg/day; prednisone, 20 mg/day; propranolol, 80 mg
3 times daily; clonidine, 0.4 mg 2 times daily; and furosemide,
60 mg daily.
In our experience with bilateral nephrectomy prior to the
routine use of cyclosporine, the fall in blood pressure was much
more dramatic than in this patient, although not always imme-
diate. Nevertheless, I believe that her hypertension was caused
by her native kidneys and that her persisting hypertension is
largely the result of cyclosporine. Not yet eliminated as con-
tributing causes are chronic rejection and recurrent essential
hypertension, although the latter is unlikely in my view. One
could argue that bilateral nephrectomy might have been post-
poned for some months. Her hypertension has been better
controlled, however, and I hope that she eventually will be able
to discontinue antihypertensive drug treatment provided renal
function is well maintained. Indeed, if her hypertension per-
sists, I would be likely to recommend eventually that she
gradually taper and then stop the cyclosporine (assuming her
renal function is well maintained). Our current research con-
centrates on whether we can maintain the excellent im-
munosuppressive effects of cyclosporine but avoid its renal
vasoconstrictive effects either by dose reduction or pharmaco-
logic manipulations. We are also continuing to investigate the
mechanism and reliability of the captopril tests for functional
renal artery stenosis.
Questions and answers
DR. GARY TOBACK (Renal Section, Mitchell Hospital, Chi-
cago, Illinois): Cyclosporine is known to induce nephrotoxic
cellular injury. Do you believe that the drug-related injury
induces hypertension?
DR. LUKE: Experimental and clinical evidence strongly sup-
ports the occurrence of renal vasoconstriction with therapeutic
doses of the drug, as I have mentioned. This hypothesis also fits
with the rapid reversibility, after reduction in the dose of
cyclosporine, of modest elevations in serum creatinine due to
cyclosporine nephrotoxicity, usually in the first few months
after transplantation. As we also have discussed, sustained
renal vasoconstriction could lead to hypertension, and we noted
a fall in blood pressure after cyclosporine administration was
discontinued and as renal blood flow improved [76]. However,
the effects of renal vasoconstriction and nephrotoxic cellular
injury are not mutually exclusive—indeed, they could be syn-
ergistic—and could each contribute to the chronic interstitial
fibrosis reported on long-term followup of some cyclosporine-
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treated patients after cardiac or renal transplantation [90, 91]. I
believe that cyclosporine-associated hypertension could either
relate to renal vasoconstriction or to renal insufficiency. Over-
all, however, the evidence for renal vasoconstriction is better
than that for cellular toxicity, at least within the therapeutic
dose range [81].
DR. JORDAN J. COHEN (Chairman, Department of Medicine,
Michael Reese Hospital and Medical Center, Chicago): You
noted that in patients whose end-stage renal disease was caused
by nephrosclerosis, bilateral native nephrectomy cures their
hypertension. You suggested that this observation might teach
us something about the pathophysiology of essential hyperten-
sion. Do you have observations in patients with similarly
well-documented nephrosclerosis as the cause of their renal
failure but who have not had native nephrectomies? What
happens to blood pressure in these patients after successful
renal transplantation when the native kidneys remain? Your
hypothesis would suggest that such patients would remain
hypertensive.
DR. LUKE: In our study, all the patients had their native
kidneys removed prior to transplantation [88]. We wished to be
certain of the diagnosis of primary hypertensive nephrosclero-
sis, and the renal histology blocks were then available for
detailed review by an independent nephropathologist. As you
know, nephrologists seldom biopsy patients in whom clinical
circumstances stongly suggest primary nephrosclerosis as a
cause of renal failure. Thus we have not studied any patients
with nephrosclerosis, retained native kidneys, a well-function-
ing allograft, and in whom we were as confident of our diagnosis
as we were in our published studies. Our clinical impression is
that prolonged remission of hypertension can occur despite
retained native kidneys, even in black recipients of a well-
tolerated allograft and despite a very likely correct clinical
diagnosis of primary hypertensive nephrosclerosis. However,
as in all reports to date, including our own, persistent hyper-
tension is more common in patients with retained native kid-
neys, regardless of the type of the primary renal disease.
Remission of essential hypertension despite retention of
native kidneys does not negate Guyton's view that at least some
patients with essential hypertension have a renal mechanism as
the proximate cause of the hypertension that is related to
inadequate adjustment of salt and water excretion. A successful
allograft takes over the role of excretion of salt and water; the
contribution of retained native kidneys, if any, to persistent or
recurrent hypertension is then, as we have discussed, due to
inappropriate renin secretion and/or to possible abnormal af-
ferent neurologic stimuli.
DR. DAVID BUSHINSKY (Renal Section, Mitchell Hospital): Is
serum creatinine a sensitive enough index of renal function, or
should one measure inulin clearance or perhaps determine
whether there are differences in the fractional dextran clearance
profiles [92]?
DR. LUKE: In transplant patients, carefully performed and
frequently repeated serial measurement of serum creatinine is
adequate for routine clinical purposes. For careful studies
designed to answer questions related to survival of nephrons,
serum creatinine is inadequate, especially for comparisons
between groups of patients. In utilizing administration of a
converting enzyme inhibitor plus a diuretic as a screening test
for functionally significant renal artery stenosis, we have found
serum creatinine to be adequate, but utilization of a convenient,
accurate and rapidly repeatable outpatient measure of GFR
would, at the very least, be likely to shorten the necessary
duration of exposure to these drugs for diagnostic purposes. In
clinical practice, however, this may not be feasible.
Da. SUSAN FELLNER (Renal Section, Mitchell Hospital): Let
us return to your speculation that cyclosporine-induced hyper-
tension is caused by afferent arteriolar vasoconstriction. It is
not known whether this is a direct effect of the drug or whether
intrarenal mechanisms are activated. Nonetheless, cyclo-
sporine-induced hypertension does not appear to be a renin-
dependent state. Would you speculate about the mechanisms
by which renal vasoconstriction causes systemic arterial hyper-
tension?
DR. LUKE: Arteriolar vasoconstriction occurs in an animal
model of cyclosporine nephrotoxity with depressed GFR but
intact tubular function [93]. Clearly the precise sites and mech-
anisms responsible for increased renal vascular resistance in
cyclosporine-associated hypertension in humans and animals
remain to be determined. Renal vasoconstriction is commonly
observed in early essential hypertension, and even in prehyper-
tensive states [94, 95]. The mechanisms responsible for the
failure of the vasoconstricted kidney to maintain normotension
are speculative but might include the inability to correct a subtle
expansion of extracellular fluid volume by excretion of salt and
water [64].
DR. SUSAN Hou (Renal Division, Michael Reese Hospital):
You noted that patients with living-related-donor transplants
have a lower incidence of hypertension at long-term followup.
You also said that one of the major causes of hypertension is
occult chronic rejection. How much of the difference between
living-related-donor transplants and cadaveric transplants is
from rejection, and how much is due to the ischemic injury that
occurs to the transplant at harvesting, injury then magnified by
cyclosporine toxicity? We know that ischemic kidneys are more
susceptible to the toxic effects of cyclosporine. Are kidneys
that have recovered from severe ATN, but recovered well,
more likely to result in hypertension than are kidneys that have
a relatively benign posttransplant course?
DR. LUKE: Acute tubular necrosis in the otherwise normal
individual is not associated with a subsequent increase in
hypertension on long-term followup [96]. In transplant patients,
tubular necrosis is more complex; that is, the syndrome can be
complicated by occult rejection and/or vascular perfusion in-
jury, depending on the amount of time the kidney has been
stored before transplantation. I am not aware of any data that
tubular necrosis, per se, has any long-term effect, however. I
agree that cyclosporine is likely to be more nephrotoxic in
situations associated with renal ischemia, as after procurement
of cadaveric kidneys. Most centers now use much smaller doses
in that situation, at least until it is established that the cadaveric
kidney is functioning well in vivo. Thus the recipients of
kidneys from live related donors may receive more cyclospor-
me and have better immunosuppression in the immediate
posttransplant period. Live related donors not only have better
one- and two-year graft survivals with conventional immuno-
suppression using azathioprine and prednisone, but also the
rate of loss of kidneys over the subsequent years is much less as
compared with cadaveric donors [97]. This difference probably
is related to reductions in the prevalence of both acute and
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chronic rejection with live related donors, and this rejection
would also contribute to a reduced prevalence of posttransplant
hypertension. The long-term effect of cyclosporine on graft
survival and incidence of hypertension in renal transplantation
using a live related donor remains to be assessed, at least in my
view, as does, therefore, its long-term therapeutic role.
DR. Hou: What about the other side of the coin? When acute
tubular necrosis occurs in conjunction with cyclosporine ther-
apy, is renal failure more prolonged than in other settings?
DR. LUKE: Yes, especially if doses of cyclosporine are not
reduced below conventional levels of 10—14 mg/kg body weight
[741. Prolonged non-function or poor renal function in the
weeks after transplantation may result in more long-term im-
paired graft function and hypertension because of the often-
associated necessity of reducing immunosuppressive drugs, the
added difficulty of diagnosing superimposed acute rejection in
an already oliguric patient on dialysis, and the likelihood that
there has been an early loss of nephrons.
Da. SERAFINO GARELLA (Department of Medicine, Michael
Reese Hospital): The patient we are discussing today had a low
renin level; furthermore, the total output of renin by the native
kidneys must have been minuscule, considering that renal
plasma flow must have been grossly reduced. I have two
questions: What are your selection criteria for nephrectomy?
Could you speculate on what mechanisms, other than renin
secretion, might be responsible for systemic hypertension ow-
ing to the presence of native kidneys?
DR. LUKE: In the patient we are discussing, we were unable
to safely discontinue giving clonidine, which reduces renin
secretion. Most investigators who have used renal vein and
allograft renin determinations and compared the results with
outcome have been unimpressed by their predictive value.
Allograft renin may be elevated because of extrarenal or
intrarenal vessel or renal parenchymal disease. Renal blood
flow to the native kidneys is low, and this situation adds to the
technical difficulty of measuring renin secretion from the native
kidneys. Our pre- and post-native-nephrectomy captopril data
[58] are consistent with a renin effect; the prenephrectomy
increases in allograft blood flow after captopril administration
were similar to those obtained after nephrectomy, whereas
captopril had no effect on allograft blood flow after nephrec-
tomy. Additional mechanisms, such as other humoral agents or
abnormal afferent nerve traffic, of course are not excluded.
We believe that native-kidney nephrectomy should be con-
sidered in patients who: (1) have good allograft function without
evidence of chronic rejection and who are stable on mainte-
nance immunosuppressive therapy, (2) have received their
allograft at least one year previously, (3) have poor blood
pressure control despite a multiple-drug regimen, and (4) do not
have renal artery stenosis. The younger the patient, the better
the graft function, the more complex and less well-tolerated the
antihypertensive drug regimen, and the more severe the hyper-
tension, the more likely is it that we and the patient would
carefully consider native-kidney surgical or chemical nephrec-
tomy. One might favor nephrectomy because captopril in-
creases allograft blood flow [58]; this finding demonstrates, at
least, that allograft blood flow can increase and that there is not
a fixed intrarenal vascular resistance. Cyclosporine-induced
vasoconstriction probably is unresponsive to treatment with
a converting enzyme inhibitor, and until we can reverse the
vasoconstriction by pharmacologic or other means, captopril
testing is likely to be of limited value in assessing patients for
nephrectomy who are receiving cyclosporine. As in the present
patient, the decision whether or not to recommend removal of
the patient's native kidneys then becomes largely a matter of
careful clinical judgment.
DR. MARSHALL LINDHEIMER (Renal Section, Mitchell Hos-
pital): If I understood, you've been looking for evidence that
the kidneys are the cause rather than the victim in nephroscle-
rosis, a search that derives from your fascinating report dem-
onstrating cures of essential hypertension by renal transplanta-
tion [88]. We might find a similar situation in the literature of
another type of allograft recipient, the pregnant woman. In the
1950s, Smythe described young black women who had acute
hypertension near term; the only abnormal finding in postpar-
tum renal biopsies was nephrosclerosis, even though the blood
pressure was normal [98]. This report was followed up by
Peyser in Israel, who described similar biopsy findings [991.
Approximately 10 years postpartum, the majority of these
women had developed essential hypertension. Then Fisher et al
in the 1980s reviewed postpartum biopsies from 176 women
who had gestational hypertension [100]. Again, these women
had only nephrosclerosis. In most of these cases, pathologists
believed the lesions were chronic, that is, not caused by
transient, acute hypertension at term. When Fisher restudied
these women, all had normal blood pressure postpartum, but
approximately 75% had developed hypertension during the next
5 years. We surveyed multiparas with transient increments in
blood pressure at term or in the immediate puerperium, and
found that the incidence of hypertension mimicked the ex-
pected prevalence for women who have reached their fifth or
sixth decades [100].
DR. LUKE: Other evidence that a renal lesion or abnormality
may be primary in "essential hypertension" has been obtained
in an animal model, the spontaneously hypertensive rat (SHR).
Prolonged treatment with antihypertensive medications, as
compared with untreated controls, prolonged life and prevented
stroke and cardiac hypertrophy, but renal vascular lesions
progressed and renal insufficiency was not prevented [101].
Finally, current evidence in humans that antihypertensive treat-
ment is reducing the incidence of end-stage renal disease due to
primary hypertensive nephrosclerosis, especially in blacks, is
unimpressive.
DR. SHELDON HIRSCH (Renal Fellow, University of Chi-
cago): If captopril administration in the absence of cyclosporine
increases renal plasma flow by blocking renin release from the
native kidneys, why can't this alteration be documented by
renin measurements?
DR. LUKE: As discussed, captopril could also act via prosta-
glandins or bradykinin [48—50]. It would, however, seem rea-
sonable that renal-vein renin concentration would be elevated
in the native-kidney renal veins. In most series the results
simply have not been predictive of response, unlike the case
with renovascular hypertension [36].
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